Efficacy profiles
| Liver metastasis | Dose of bevacizumab | ||||
|
No
(N=20) |
Yes
(N=10) | 7.5 mg/kg (N=21) | 15 mg/kg (N=9) | Overall (N=30) | |
| Best tumor response | |||||
| CR | 1 (5.0%) | 0 | 1 (4.8%) | 0 | 1 (3.3%) |
| PR | 17 (85.0%) | 4 (40.0%) | 15 (71.4%) | 6 (66.7%) | 21 (70.0%) |
| SD | 2 (10.0%) | 3 (30.0%) | 2 (9.5%) | 3 (33.3%) | 5 (16.7%) |
| PD | 0 (0%) | 3 (30.0%) | 3 (14.3%) | 0 | 3 (10.0%) |
| ORR | 18 (90.0%) | 4 (40.0%) | 16 (76.2%) | 6 (66.7%) | 22 (73.3%) |
| CBR | 20 (100%) | 6 (60.0%) | 17 (81.0%) | 9 (100%) | 26 (86.7%) |
| DCR | 18 (90.0%) | 7 (70.0%) | 16 (76.2%) | 9 (100%) | 25 (83.3%) |
CBR, clinical benefit rate; CR, complete remission; DCR, disease control rate; ORR, objective response rate; PD, progressive disease; PR, partial remission; SD, stable disease.